TITLE

Niacin Beats Ezetimibe Head to Head

PUB. DATE
January 2010
SOURCE
Travel Medicine Advisor;Jan2010 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates on several drugs from the U.S. Food and Drug Administration (FDA). A study revealed that adding niacin to statin increases HDL-cholesterol (HDL-C). FDA has issued a notice which concerns the effects of combining clopidogrel (Plavix) with omeprazole (Prilosec). Research revealed that darbepoetin alfa (Aranesp), a common drug used in patients with chronic kidney disease can provide an increased risk of stroke on patients.
ACCESSION #
48667570

 

Related Articles

  • Intelligence. Koroneos, George // Pharmaceutical Representative;Feb2009, Vol. 39 Issue 2, p8 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Pharmaceutical Research and Manufacturers of America has modified its guidelines for advertising of prescription drugs. The U.S. Food and Drug Administration has backed Vytorin in reducing arterial plaque in...

  • A Screening Study of Drug-Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel. Floyd, J S; Kaspera, R; Marciante, K D; Weiss, N S; Heckbert, S R; Lumley, T; Wiggins, K L; Tamraz, B; Kwok, P-Y; Totah, R A; Psaty, B M // Clinical Pharmacology & Therapeutics;May2012, Vol. 91 Issue 5, p896 

    An analysis of a case-control study of rhabdomyolysis was conducted to screen for previously unrecognized cytochrome P450 enzyme (CYP) 2C8 inhibitors that may cause other clinically important drug-drug interactions. Medication use in cases of rhabdomyolysis using cerivastatin (n = 72) was...

  • Omeprazole's effect on clopidogrel. Elliott, William T. // Clinical Oncology Alert;Jan2010 Supplement 2, p2 

    The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) on avoiding the combination of clopidogrel with omeprazole to prevent reducing the effectiveness of clopidogrel by about half. The warning is based on the results of studies published in 2009 which suggested...

  • GUIDANCE ROUND-UP.  // Pulse;3/14/2012, Vol. 72 Issue 9, p13 

    The article offers information related to health including the notice issued by the U.S. Food and Drug Administration regarding the interaction of statins and HIV drugs which can increase the risk of myopathy, updated statin labels ordered by the U.S. Food and Drug Administration for liver...

  • "High-5" for statins; assurance of safety, efficacy.  // Medical Marketing & Media;Oct2001, Vol. 36 Issue 10, p19 

    Reports the efficacy of statins drugs in prolonging lives and preventing heart disease in the U.S. Authority of the usage from the U.S. Food and Drug Administration; Therapeutic contents of satins; Other benefits derived from the product.

  • New info about statin safety affects millions. Clever, Henry // St. Charles Journal;4/4/2012, Vol. 47 Issue 14, pB6 

    The article focuses on the new information on statin issued by the Food and Drug Administration (FDA) about its threat to damage the liver as a rare side effect as well as development of diabetes and cognitive impairment.

  • Why FDA Failures Threaten Our Safety.  // Health & Stress;2002, Issue 1, p2 

    Focuses on the controversy on the statin drug Rezulin approval in the Food and Drug Authority (FDA) in the United States. Association of liver failure with statin drugs; Lack of personnel to evaluate and monitor adverse drug reactions; Influence of drug companies on the approval and regulatory...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Oct2008 Pharmacology, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has issued warnings for the drugs Simvastatin and Exenatide in October 2008. Patients are being warned not to take simvastatin if they are being treated with amiodarone because it puts them at a higher risk for rhabdomyolysis....

  • FDA actions. Elliot, William T. // Neurology Alert;Apr2012 Pharmacology Watch, p2 

    The article reports on the warning and requirement of the Food and Drug Administration (FDA) for label changes to all statins to indicate risk of elevated blood sugar and reversible cognitive changes based on a review of multiple studies showing increases in blood sugar associated with the drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics